K Ray Chaudhuri (King’s College and King’s College Hospital, London, UK) and Nataliya Titova (RNRMU, Moscow, Russia and King’s College Hospital, London, UK), both on our European editorial board, took the time to discuss their recently published review article with us entitled: Societal Burden and Persisting Unmet Needs of Parkinson’s Disease, freely available to access in European Neurological Review here.
1. How great is the societal burden of Parkinson’s disease (PD), has it changed over recent decades and is it likely to increase in the future? (0:04)
2. What do you consider to be the most pressing unmet needs in PD – do they include better management of motor symptoms or non-motor symptoms or both? (1:01)
3. How far has the understanding of PD pathophysiology improved in recent years – do new concepts such as the gut-brain hypothesis help disease understanding and do they provide potential routes to new therapies? (2:01)
4. Efforts to develop disease-modifying treatments for PD have so far failed to show efficacy in clinical trials; are there any newer treatments in development that have better potential for success – should new treatments be directed at targets other than the dopaminergic system? (2:46)
5. Whilst effective disease-modifying therapies are not available, is there any scope for improving or maintaining the efficacy of levodopa treatment to reduce OFF episodes and wearing OFF? (3:24)
Speaker disclosures: K Ray Chaudhuri has participated on scientific advisory boards and/or received honoraria for scientific advice from Abbott, Boehringer-Ingelheim, GSK, Serono, Teva, UCB and Britannia Pharmaceuticals. Nataliya Titova has received honoraria for lectures in educational symposia from Teva and UCB.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
Share this Video
Related Videos In Parkinson's Disease
Heinz Reichmann, EAN 2021: OPTIPARK Study Findings
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]
Heinz Reichmann, EAN 2021: Levodopa-based Drugs in the Treatment of Parkinson’s Disease
We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]
Stephen Pasternak, AD/PD 2021: Phase 2 trial Investigating Ambroxol as a Treatment for Parkinson’s Disease Dementia
It was a great pleasure to speak with Stephen Pasternak (University of Western Ontario, Ontario, Canada) to discuss the phase 2 trial investigating ambroxol as a disease-modifying treatment for Parkinson’s Disease dementia. The abstract entitled ‘Ambroxol as a Disease-modifying Treatment for Parkinson’s Disease Dementia: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial’ was presented at The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!